Welcome to our dedicated page for Icad news (Ticker: ICAD), a resource for investors and traders seeking the latest updates and insights on Icad stock.
This page provides a historical news archive for iCAD, Inc. (formerly NASDAQ: ICAD), a company that described itself as a global leader in clinically proven AI-powered breast health and cancer detection solutions. Before becoming a wholly owned subsidiary of RadNet, Inc., iCAD regularly issued news releases detailing its product developments, clinical research, commercial partnerships, and financial performance.
Readers can review announcements about the ProFound Breast Health Suite, which iCAD characterized as an industry-leading AI-powered mammography analysis platform for breast cancer detection, density assessment, and risk evaluation. News items include updates on FDA clearances for ProFound Detection versions, the introduction of ProFound Cloud as a scalable SaaS platform, and collaborations that integrated iCAD’s AI technology into radiology information systems, PACS platforms, and cloud-based precision imaging networks.
The archive also covers financial news, such as quarterly and annual results, trends in annual recurring revenue associated with the company’s transition to a subscription and cloud-based model, and commentary from management on operating performance. Additional releases highlight clinical abstracts and presentations at major conferences, where research collaborators evaluated iCAD’s AI tools for early detection, risk prediction, and breast arterial calcification assessment across diverse populations.
Because iCAD completed a merger with RadNet in July 2025 and its common stock ceased trading independently, the ICAD news feed now serves as a record of historical communications from iCAD’s time as a standalone public company. Investors, clinicians, and researchers can use this archive to understand how the company described its technology, strategy, and clinical evidence prior to its integration into RadNet’s diagnostic imaging and digital health portfolio.
Dana Brown has been appointed as the Executive Chair of the Board at iCAD, effective January 11, 2023. Previously a board member since February 2022 and former Chief Strategy and Operations Officer at Susan G. Komen, Brown aims to leverage her experience to bolster iCAD's cancer detection and therapy solutions. The company is expected to form crucial partnerships with organizations like Google Health and Radiology Partners for growth. Outgoing Chair Timothy Irish is acknowledged for his role in the company's significant partnerships.
iCAD (NASDAQ: ICAD) announced that Solis Mammography will participate in the upcoming ProFound Insights, ProFound Impact webinar on December 14, 2022. Chirag Parghi, MD, Chief Medical Officer of Solis Mammography, will discuss the clinical value of ProFound AI, iCAD’s breast imaging solution. With over one million women served annually through its 100+ locations, Solis Mammography integrates ProFound AI to enhance clinical decisions and improve patient care. The companies aim to extend collaboration to assess cardiovascular disease risk using mammogram data.
iCAD has announced a strategic partnership with Google Health, marking the latter's first collaboration with a mammography AI vendor. This agreement aims to integrate Google’s AI technology into iCAD’s portfolio, enhancing their breast cancer detection capabilities. The collaboration is expected to improve the accuracy and efficiency of mammography and expand access to innovative breast imaging solutions globally. iCAD will leverage Google Cloud’s infrastructure to transition its offerings to cloud-based solutions, enhancing scalability and reaching underserved regions.
NASHUA, N.H., Nov. 15, 2022 - iCAD, a leader in medical technology, has announced that CEO Stacey Stevens will participate in the 13th Annual Craig-Hallum Alpha Select Conference on November 17 in New York City. The event will provide a platform for investor engagement through one-on-one meetings. This participation highlights iCAD's commitment to advancing cancer detection and therapy solutions. Interested investors can arrange meetings via Craig-Hallum representatives. For more details, visit www.icadmed.com.
iCAD (NASDAQ: ICAD) will be prominently featured at HLTH 2022, a major health industry conference held from November 13-16 at the Venetian Hotel in Las Vegas. The event will see over 8,500 senior leaders collaborate on pressing healthcare issues. iCAD's President and CEO, Stacey Stevens, will speak about enhancing breast cancer screening through AI on November 14, from 1:55 to 2:35 pm in the Google Health Theater Room. This participation underscores iCAD's commitment to innovative cancer detection and therapy solutions.
iCAD reported a Q3 2022 revenue of $6.4 million, down 32% year-over-year, attributed to a 49% drop in product revenue. Cost-cutting measures aim to reduce expenses by over $3 million annually. A strategic shift towards a subscription-based model has resulted in increased demand, with more subscriptions booked in Q3 than in the first half of 2022. The new Subscription Annual Recurring Revenue (S-ARR) metric aims to highlight progress in this area. The net loss for Q3 2022 was $3.9 million, compared to $2.2 million in Q3 2021.
iCAD has announced a strategic multi-year partnership with Radiology Partners, the largest radiology practice in the U.S., to expand the adoption of iCAD's Breast AI Suite. This collaboration aims to enhance breast cancer screening access for millions of women nationwide. The agreement includes an initial order from Radiology Partners, enabling the deployment of iCAD's technologies across its expansive network, which serves over 3,000 facilities. The Breast AI Suite incorporates advanced AI tools for improved mammography accuracy and personalized risk evaluation.
iCAD, Inc. (NASDAQ: ICAD) announced it will release its third-quarter financial results for the period ending September 30, 2022, after market close on November 10, 2022. A conference call is scheduled for 4:30 PM ET on the same day, allowing investors and analysts to discuss the outcomes. The information aims to provide insights into the company's ongoing efforts in cancer detection and therapy solutions, reflecting its position as a leader in medical technology.
iCAD, Inc. (NASDAQ: ICAD) has entered a strategic collaboration with Solis Mammography to enhance cardiovascular disease (CVD) detection in women through mammography. The partnership aims to develop an AI solution leveraging ProFound AI technology to identify breast arterial calcifications, a key indicator of heart disease risk. The initiative addresses a critical health issue, as heart disease is the leading cause of death among women in the U.S. This collaboration builds upon their existing relationship, with Solis Mammography already using iCAD's technology across its network.
iCAD, a leader in medical technology focused on cancer detection and therapy, announced its participation in the Lake Street Capital Markets 6th Annual Best Ideas Growth Conference on September 14, 2022, in New York City. Stacey Stevens, President and CEO, will meet with investors at the event. Interested parties can schedule meetings through Lake Street Capital representatives. iCAD continues to innovate with its ProFound AI technology, though it faces potential risks and uncertainties, including market acceptance and regulatory factors.